towards significant association with post-operative antibiotic use (p Z 0.05 & 0.08). No other factors associated with sub-acute post-operative complications, including age, race, menstrual status, tumor stage, histology, grade, receptor status, laterality, quadrant, number of foci, number of nodes excised or positive, number of re-excisions, time to surgery after diagnosis, time to hormonal therapy after surgery, or IORT treatment time or applicator size. Conclusion: Here we demonstrate in a single institution, retrospective study that women tolerate IORT well. The type and frequency of sub-acute post-operative complications compare well with those seen in surgery without IORT. Further review with a larger cohort and matched controls may help provide additional information about this relatively new therapeutic modality.
Purpose/Objective(s): Targeted Intraoperative Radiation Therapy (IORT) has been explored in clinical studies and used as an alternative to conventional whole breast irradiation (WBI) in early stage breast cancers. This study utilized the ASTRO 2009 consensus and the TARGIT-A and TAR-GIT-B criteria in selecting patients. We report the early radiation treatment related outcomes of our single institution prospective cohort study using the Intrabeam system. Materials/Methods: All eligible patients since September 2011 were entered consecutively into the cohort. Patients meeting the criteria of the ASTRO consensus, aside from age ! 60, and the TARGIT-A trial received IORT as the sole and definitive radiation treatment. If surgical pathology revealed findings incompatible with IORT treatment alone, then whole breast external beam radiation (EBRT) was added without a boost. IORT related complications, cosmesis, and early oncologic outcomes were assessed. Locoregional recurrence and toxicities were compared to TAR-GIT-A with a chi-square goodness of fit test, using the TARGIT-A outcomes as expected values. Patient characteristics were also compared to TARGIT-A. Results: A total of 80 patients have been followed prospectively after having received breast IORT treatment with a median follow-up of 2.77 years. 73% of patients received IORT as their only form of radiation treatment. The remainder (27%) received additional whole breast radiation, as the patients did not fit the TARGIT-A or ASTRO consensus guidelines for partial breast irradiation. There were three local recurrences (3.75%) noted in the treated breast. All three recurrences took place about 2 years post-IORT treatment. In TARGIT-A, the 5-year risk for local recurrence was 3.3% (95% CI 2.1e5.1). However, after a median follow up of 2.4 years, the incidence of locoregional recurrence was 31 out of 1679 patients (1.8%). When comparing the incidence of locoregional recurrence in our cohort with the TARGIT-A cohort, there was no statistical difference (pZ 0.19). Patient toxicities were also evaluated. There was no statistical difference in the rates of hematoma, seroma, and skin breakdown or delayed wound healing (pZ 0.82, 0.60, and 0.87 respectively). Infection requiring IV antibiotics or surgical intervention and RTOG toxicity of grade 3 or 4 were found to be statistically different (pZ 0.003 and 0.011 respectively). To measure cosmesis, the Harvard Breast Cosmesis scoring system was used. In patients that had documented breast cosmesis scores, 76% of patients had excellent cosmesis, and 24% had good cosmesis. Conclusion: Treatment outcomes in patients that received IORT are comparable to the results of the TARGIT-A trial with respect to locoregional control and patient toxicities. Excellent and good cosmetic outcomes were achievable in this early report of our study. Purpose/Objective(s): An essential component in the management of early stage and locally advanced breast cancer is whole breast irradiation (WBI), which is typically delivered in the supine position. However, the supine setup may have the limitation of infra-mammary folds, more inclusion of lung and heart, and lateral displacement of breast. In this work, we present the dosimetric results of a prospective study of prone positioning WBI. Materials/Methods: Twenty-six patients were treated with prone breast positioning in our clinic since 08/2014. CT simulation was conducted with 2.5mm slice thickness. Patients were positioned on the prone breast board with both arms above the head and hands holding the bar to reduce body rotation. The contralateral breast was tucked away and the head was turned away from the treated breast. The planning target volume (PTV) was contoured by the radiation oncologist. Two opposed tangential fields using 6MV photon beams with the field-in-field technique were applied to obtain target coverage and dose uniformity. Cone beam CT (CBCT) was acquired to ensure the prone setup accuracy. Heterogeneity correction was applied in treatment planning. DVH for PTV, ipsilateral lung, total lung, and heart were calculated. Results: Twenty-six patients were divided into three categories based on the PTV volume: 7 in the small breast group (PTV<800cc), 14 in the medium breast group (PTVZ800w1600cc), and 5 in the large breast group (PTV>1600cc). All plans obtained adequate target coverage, i.e., !95% of PTV receiving 95% of the prescribed dose (Rx). The average homogeneity index (HIZDmax/Rx) was 104.6AE2.0%. For the large breast group, due to the relatively large separation between critical structures and the target volume, the ipsilateral lung's V20 w 0, V5 < 2% and the mean dose to the total lung < 1 Gy. For the left-sided breast radiation therapy, the mean dose to the heart was 1.7AE0.9 Gy and the heart's V5 was 3.3AE5.2%. No infra-mammary skin folding was observed for all prone setups. Conclusion: The prone setup for whole breast irradiation has demonstrated favorable ipsilateral lung and heart dose while achieving better dose uniformity. Patients with large or pendulous breasts in particular benefit from prone positioning with reduced toxicity in the heart and lung and skin folding. 27-45.45 ). In a multivariable analysis of time to death, treatment group, LVSI, and ECE were all found to be statistically significant predictors (pZ 0.0207, 0.0298, 0.0026 respectively). Effects of age, stage, BMI, race, tumor margins, and grade were not found to be significant predictors of either survival or recurrence.
Conclusion: As seen in other retrospective reviews, we found that mastectomy without RT vs. BCT in early stage patients and the presence of LVSI both adversely impacted overall survival. We additionally found ECE to be an adverse risk factor for death and negative predictor for overall survival. Given the increased risk of death with LVSI and ECE, we recommend that these adverse pathological factors be utilized as prognostic determinants, and incorporated in the treatment decision making for TNBC. 
